Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/Nkarta, Inc./ 10-Q

Quarterly Report · 10-Q

Nkarta, Inc.

NKTXNASDAQEQUITYCurrent

Quarterly Report

Filed Aug 10, 2026Accepted Aug 10, 2026, 4:19 PM EDTCIK 1787400Accession 0001787400-26-000017
View company →Permanent SEC source ↗
Share

Company context

Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for people living with autoimmune diseases. By harnessing the power of the innate immune system to eliminate pathogenic B cells driving the autoimmune response, Nkarta is advancing novel cell therapies engineered for deep therapeutic impact. The on-demand availability and outpatient dosing of our CAR-NK cells enables a broad population of patients with different autoimmune conditions to conveniently access NK cell therapy in community health settings. For more information, please visit the company’s website at www.nkartatx.com.

Current securities

NKTXNASDAQ · EQUITY · Current

Recent company filings

  1. Results of Operations and Financial ConditionAug 10, 2026
  2. 4 filingJun 22, 2026
  3. Submission of Matters to a Vote of Security HoldersJun 11, 2026
  4. 4 filingJun 11, 2026
  5. 10-Q filingMay 12, 2026

Registered securities in this filing

Nkarta, Inc. · 10-Q · Filed 2026-08-10

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, $0.0001 par value per share

Symbol
NKTX
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: C_b54785e7-c6e0-48a5-aa5d-b5a2aafb0ac3

Dimensions: Not supplied

Accession 000178740026000017 · 1 registered-security cover member

Read the exact SEC filing ↗

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.